Martin S. Hirsch, MD
It has now been 7 years since the first clinical descriptions of the acquired immunodeficiency syndrome (AIDS), 4 years since HIV-1 was established as its cause, and 2 years since zidovudine (azidothymidine, Retrovir) was shown to improve survival from advanced HIV-1 infection (1). Moreover, intensive investigation into the replicative mechanisms of HIV-1 has led to a veritable flood of new agents that inhibit viral replication in vitro and will require further clinical investigation (2, 3). With this flood of information has come a tidal wave of rising public expectations that threatens the ability to conduct controlled clinical trials. An understanding
Hirsch MS. The Rocky Road to Effective Treatment of Human Immunodeficiency Virus (HIV) Infection. Ann Intern Med. ;110:1–3. doi: 10.7326/0003-4819-110-1-1
Download citation file:
Published: Ann Intern Med. 1989;110(1):1-3.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use